Working... Menu

A Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors (SPRING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02786719
Recruitment Status : Active, not recruiting
First Posted : June 1, 2016
Last Update Posted : May 31, 2019
Texas Children's Hospital
Information provided by (Responsible Party):
Sarah Whittle, Baylor College of Medicine

Brief Summary:

Patients will be asked to participate in this study because patients have been diagnosed with high-risk neuroblastoma, a common childhood cancer which has aggressive features. If left untreated, high-risk neuroblastoma is fatal. Children with high-risk neuroblastoma often respond to current available treatments, but there is a high risk that the cancer will return.

This study will test the safety of giving standard induction treatment for high-risk neuroblastoma without one of the drugs commonly used to prevent side effects. Current treatment for high-risk neuroblastoma includes anti-cancer drugs (chemotherapy), surgery, radiation therapy and high-dose chemotherapy with hematopoietic stem cell rescue. Treatment takes about one year to complete and occurs in 3 phases: induction, consolidation, and maintenance. This study is limited to the induction phase of treatment.

Induction therapy includes six chemotherapy drugs given in different combinations every 3 weeks for a total of 6 courses. For the past decade, induction chemotherapy has been followed by a drug called granulocyte colony stimulating factor (G-CSF, filgrastim, peg-filgrastim, Neupogen, or Neulasta) to prevent side effects from the chemotherapy. G-CSF is routinely given to patients with high risk neuroblastoma after chemotherapy to stimulate white blood cell production and shorten the time period when the absolute neutrophil count (ANC), a type of white blood cell, is low after chemotherapy. G-CSF is known to shorten the period of low ANC by approximately 3 days. When the ANC is lowest, a patient is most at risk of getting a bacterial infection.

Recent lab experiments in mice have shown that neuroblastoma tumor cells may respond to G-CSF by growing faster and metastasizing (spreading to other parts of the body). There have been no clinical trials comparing the survival of children with high risk neuroblastoma with or without G-CSF. This clinical trial is the first step towards giving induction chemotherapy with less G-CSF.

The goal of this study is to determine if it is safe to give induction chemotherapy to children with neuroblastoma without giving G-CSF routinely.

Condition or disease Intervention/treatment Phase
Neuroblastoma Drug: Topotecan Drug: Cyclophosphamide Drug: Cisplatin Drug: Etoposide Drug: Vincristine Drug: Doxorubicin Drug: Sargramostim Not Applicable

Detailed Description:


CYCLE 1+2: Topotecan and cyclophosphamide

Cycle 3+5: Cisplatin and Etoposide

Cycle 4+6: Vincristine, Cyclophosphamide and Doxorubicin

Stem cell collection: After the third cycle of chemotherapy, stem cells will be collected for possible stem cell transplantation at a later date using apheresis. In order to have enough stem cells present in the blood, the patient will need to receive daily G-CSF injections before this collection.

Surgery: After the 5th cycle of chemotherapy, most patients will have surgery to remove as much remaining tumor as possible.

Growth factor support: Growth factors to increase the number of white blood cells, G-CSF and GM-CSF(granulocyte-macrophage colony stimulating factor) will not be given routinely in this study. GM-CSF will be given for patients who have serious bacterial infections or delays in administering chemotherapy because of low neutrophil counts. All people enrolled on the study will receive GM-CSF prior to having surgical removal of the main tumor. All people enrolled on the study will also receive G-CSF prior to having patients stem cells collected.

Optional survey: This research study includes an optional survey regarding quality of life while on the study. This survey will be filled out after cycles 1 and 4 of chemotherapy.

Drug Shortages:

In the event of a drug shortage of a medication that is not a G-CSF or GM-CSF product, the provider may use best clinical judgment regarding omission of the agent or substitution with a different agent. The medical and research records of study patients should reflect that the patient was informed of any delays and/or modifications in protocol therapy related to the shortage of the agent and the associated risks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Safety Pilot Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors
Study Start Date : June 2016
Actual Primary Completion Date : March 22, 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma

Arm Intervention/treatment
Experimental: Neuroblastoma treatment without G-CSF
Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
Drug: Topotecan
CYCLE 1+2 (given by intravenous catheter daily for 5 days)

Drug: Cyclophosphamide
CYCLE 1+2 (given by intravenous catheter daily for 5 days)

Drug: Cisplatin
Cycle 3+5 (given daily x 4 days)

Drug: Etoposide
Cycle 3+5 (given daily for 3 days)

Drug: Vincristine
Cycle 4+6 (given daily for 3 days)

Drug: Cyclophosphamide
Cycle 4+6 (given daily for 2 days)

Drug: Doxorubicin
Cycle 4+6 (given daily for 3 days)

Drug: Sargramostim
Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)

Primary Outcome Measures :
  1. the incidence of infections in chemotherapy cycles NOT followed by hematopoietic growth factors [ Time Frame: through study completion, approximately 5 months ]

Secondary Outcome Measures :
  1. incidence of delay in chemotherapy administration due to prolonged neutrophil recovery [ Time Frame: through study completion, approximately 5 months ]
  2. the number of antibiotic days and hospital days due to fever and/or infection [ Time Frame: through study completion, approximately 5 months ]
  3. number of platelet transfusions in in patients undergoing induction chemotherapy [ Time Frame: through study completion, approximately 5 months ]
  4. the response rate following induction chemotherapy without prophylactic granulocyte colony stimulating factor (G-CSF) [ Time Frame: through study completion, approximately 5 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age greater than 12 months and less than 18 years old at diagnosis
  • Newly diagnosed neuroblastoma or ganglioneuroblastoma as verified by histology and/or demonstration of tumor cells in bone marrow with elevated urinary catecholamine metabolites
  • Must meet criteria for High Risk disease

    • Patients with International Neuroblastoma Staging System (INSS) stage 4 disease are eligible with the following: MYCN gene amplification (greater than four-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features, Age greater than 18 months ( greater than 547 days) regardless of biologic features, Age 12 -18 months (365 - 547 days) with any of the following unfavorable biologic features (unfavorable pathology and/or DNA index = 1) or any biologic feature that is indeterminate/unsatisfactory/unknown
    • Patients with INSS stage 3 disease are eligible with the following: MYCN amplification, regardless of age or additional biologic features, Age greater than 18 months ( greater than 547 days) with unfavorable pathology, regardless of MYCN status
    • Patients with INSS stage 2a/2b with MYCN amplification regardless of age or additional biologic features
    • Patients greater than or equal to 365 days initially diagnosed with INSS stage 1 or 2 who progressed to a stage 4 without interval chemotherapy
  • Patients may have had no prior systemic therapy except: Localized emergency radiation to sites of life threatening or functioning disease, No more than 1 cycle of chemotherapy according to low or intermediate risk regimens prior to determination of MYCN amplification and histology, as long as the patient DID NOT receive any type of granulocyte colony stimulating factor (G-CSF) as part of that therapy.
  • Patients must have adequate hematopoietic function defined as: Absolute neutrophil count (ANC) greater than or equal to 750/μL, Platelet count greater than or equal to 75,000/μL, The above criteria do not have to be met if the patient has bone marrow involvement of tumor.
  • Patients must have adequate liver function defined as: Direct bilirubin less than or equal to 1.5 mg/dL or total bilirubin ≤ 1.5 mg/dL, aspartate aminotrasnferase (AST) and alanine aminotransferase (ALT) less than or equal to10 x upper limit of normal for age
  • Patients must have adequate renal function as defined as: Creatinine clearance (CrCl) or radioisotope glomerular filtration rate (GFR) greater than or equal to 70 mL/min/.73 m2 OR A serum creatinine based on age/gender.
  • Patients must have adequate cardiac function as defined as: Shortening fraction of greater than or equal to 27 % by echocardiogram, or Ejection fraction of greater than or equal to 50 % by radionuclide angiogram

Exclusion Criteria:

  • Patients who do not meet inclusion criteria
  • Patients who are pregnant or lactating
  • Patients who have received G-CSF since the time of diagnosis of the current disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02786719

Layout table for location information
United States, California
Rady Children's Hospital
San Diego, California, United States, 92123
United States, Texas
Texas Children's Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
Texas Children's Hospital
Layout table for investigator information
Principal Investigator: Sarah Whittle, MD, BA Baylor College of Medicine

Layout table for additonal information
Responsible Party: Sarah Whittle, Instructor, Baylor College of Medicine Identifier: NCT02786719     History of Changes
Other Study ID Numbers: H-38179 (SPRING)
SPRING ( Other Identifier: Baylor College of Medicine )
First Posted: June 1, 2016    Key Record Dates
Last Update Posted: May 31, 2019
Last Verified: May 2019

Keywords provided by Sarah Whittle, Baylor College of Medicine:

Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Liposomal doxorubicin
Etoposide phosphate
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Antibiotics, Antineoplastic